Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky Join 4SC AG
News Jan 17, 2015
4SC AG has announced that Prof. Dr. Helga Rübsamen-Schaeff and Joerg von Petrikowsky have been appointed as new members of its Supervisory Board.
Since 2006, Prof. Dr. Rübsamen-Schaeff has acted as Managing Director and CEO of AiCuris GmbH, a German biopharma company founded by her. In this capacity, she was responsible, among other things, for securing a licensing deal with US pharmaceutical company Merck with a total value of up to EUR 442 million plus royalties.
From 1994 to 2006 she held senior research positions at Bayer AG, Leverkusen, first as Vice President and Head of Antiviral Research from 1994 to 2001, later as Senior Vice President and Global Head of Bayer's Anti-Infective Research.
After obtaining a degree and doctorate in chemistry and working as a guest scientist at various international institutions including the US-universities Harvard and Cornell, she was Scientific and Managing Director at the Institute of Biomedical Research Georg-Speyer-Haus in Frankfurt (now Institute for Tumor Biology and Experimental Therapy) for six years.
In 1988 she was appointed as Professor of Biochemistry and Virology at the University of Frankfurt. In 2014 she was appointed as member of the Board of Partners and of the Supervisory Board of German pharmaceutical and chemical group Merck KGaA, Darmstadt, also acting as Chair of the company's Research Council since then.
Joerg von Petrikowsky has more than 30 years of experience as an auditor and tax adviser focusing in particular on the auditing and advising of international pharmaceutical, medical technology and biotechnology companies. Working for Arthur Andersen (1984-2002) and Ernst & Young (2002-2013), he held various senior positions including Head of Life Sciences at Ernst & Young. On the Supervisory Board of 4SC, Mr. von Petrikowsky will act as Chairman of the Audit Committee and as the independent financial expert.
Both terms of office will initially run until the end of the Annual General Meeting that resolves on formally approving the actions of the Supervisory Board for the financial year 2014. Prof. Dr. Rübsamen-Schaeff and Mr. von Petrikowsky will replace the Supervisory Board members Dr. Thomas Werner and Klaus Kühn who recently stepped down. Thus the Supervisory Board of 4SC AG chaired by Dr. Clemens Doppler again consists of six members.
Dr. Clemens Doppler, Chairman of the Supervisory Board of 4SC AG, comments: "We are very pleased that with Helga Rübsamen-Schaeff and Joerg von Petrikowsky we have been able to attract two highly competent and renowned individuals for the Supervisory Board of 4SC AG."
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Prostate- and Colon Cancer Targeted With Tapeworm DrugNews
Recently researchers found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE